Kaplan-Meier survival curves. Survival curves for OS (A) and DFS (B) over ∼36 months of overlapping posttransplant follow-up across trial arms and CIBMTR cohorts. HRs for OS and DFS are based on analyses over the entirety of available follow-up for all study cohorts. One additional death in the omidubicel arm, and 2 additional deaths in the UCB arm were observed in the trial after 36 months. One additional DFS event was observed in the UCB arm after 36 months. The survival curves are unadjusted, whereas the HRs represent adjusted analyses. Haplo, haploidentical.